Physics and small-scale dosimetry of -emitters for targeted radionuclide therapy: The case of .

Abstract

Monte Carlo simulations have been considered for a long time the gold standard for dose calculations in conventional radiotherapy and are currently being applied for the same purpose in innovative radiotherapy techniques such as targeted radionuclide therapy (TRT). We present in this work a benchmarking study of the latest version of the Transport d'Ions Lourds Dans l'Aqua & Vivo (TILDA-V) Monte Carlo track structure code, highlighting its capabilities for describing the full slowing down of -particles in water and the energy deposited in cells by -emitters in the context ofTRT. We performed radiation transport simulations of -particles (10keV -100MeV ) in water with TILDA-Vand the Particle and Heavy Ion Transport code System (PHITS) version 3.33. We compared the predictions of each code in terms of track parameters (stopping power, range and radial dose profiles) and cellular S-values of the promising radionuclide astatine-211 ( ). Additional comparisons were made with available data in theliterature. The stopping power, range and radial dose profiles of -particles computed with TILDA-Vwere in excellent agreement with other calculations and available data. Overall, minor differences with PHITS were ascribed to phase effects, that is, related to the use of interaction cross sectionscomputed for water vapor or liquid water. However, important discrepancies were observed in the radial dose profiles of monoenergetic -particles, for which PHITS results showed a large underestimation of the absorbed dose compared to other codes and experimental data. The cellular S-values of computed with TILDA-V agreed within 4% with the values predicted by PHITS andMIRDcell. The validation of the TILDA-Vcode presented in this work opens the possibility to use it as an accurate simulation tool for investigating the interaction of -particles in biological media down to the nanometer scale in the context of medical research. The code may help nuclear medicine physicians in their choice of -emitters for TRT. Further research will focus on the application of TILDA-Vfor quantifying radioinduced damage on the deoxyribonucleic acid (DNA) molecule.